» Articles » PMID: 38398707

Mitochondria in Alzheimer's Disease Pathogenesis

Overview
Journal Life (Basel)
Specialty Biology
Date 2024 Feb 24
PMID 38398707
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder that primarily affects persons aged 65 years and above. It causes dementia with memory loss and deterioration in thinking and language skills. AD is characterized by specific pathology resulting from the accumulation in the brain of extracellular plaques of amyloid-β and intracellular tangles of phosphorylated tau. The importance of mitochondrial dysfunction in AD pathogenesis, while previously underrecognized, is now more and more appreciated. Mitochondria are an essential organelle involved in cellular bioenergetics and signaling pathways. Mitochondrial processes crucial for synaptic activity such as mitophagy, mitochondrial trafficking, mitochondrial fission, and mitochondrial fusion are dysregulated in the AD brain. Excess fission and fragmentation yield mitochondria with low energy production. Reduced glucose metabolism is also observed in the AD brain with a hypometabolic state, particularly in the temporo-parietal brain regions. This review addresses the multiple ways in which abnormal mitochondrial structure and function contribute to AD. Disruption of the electron transport chain and ATP production are particularly neurotoxic because brain cells have disproportionately high energy demands. In addition, oxidative stress, which is extremely damaging to nerve cells, rises dramatically with mitochondrial dyshomeostasis. Restoring mitochondrial health may be a viable approach to AD treatment.

Citing Articles

Alzheimer's Disease: Exploring Pathophysiological Hypotheses and the Role of Machine Learning in Drug Discovery.

Dominguez-Gortaire J, Ruiz A, Porto-Pazos A, Rodriguez-Yanez S, Cedron F Int J Mol Sci. 2025; 26(3).

PMID: 39940772 PMC: 11816687. DOI: 10.3390/ijms26031004.


The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.

Leisgang Osse A, Kinney J, Cummings J Alzheimers Dement (N Y). 2025; 11(1):e70050.

PMID: 39935614 PMC: 11812129. DOI: 10.1002/trc2.70050.


Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.

Hernandez P, Rackles E, Alboniga O, Martinez-Lage P, Camacho E, Onaindia A J Extracell Vesicles. 2025; 14(2):e70043.

PMID: 39901643 PMC: 11791017. DOI: 10.1002/jev2.70043.


Advancing Alzheimer's Disease Modelling by Developing a Refined Biomimetic Brain Microenvironment for Facilitating High-Throughput Screening of Pharmacological Treatment Strategies.

Mohd Murshid N, Mohd Sahardi N, Makpol S Int J Mol Sci. 2025; 26(1.

PMID: 39796097 PMC: 11719782. DOI: 10.3390/ijms26010241.


Mitochondrial Alterations in Alzheimer's Disease: Insight from the 5xFAD Mouse Model.

Keskinoz E, Celik M, Toklucu E, Birisik K, Erisir A, Oz-Arslan D Mol Neurobiol. 2024; .

PMID: 39658775 DOI: 10.1007/s12035-024-04632-4.


References
1.
Van Bulck M, Sierra-Magro A, Alarcon-Gil J, Perez-Castillo A, Morales-Garcia J . Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease. Int J Mol Sci. 2019; 20(3). PMC: 6386829. DOI: 10.3390/ijms20030719. View

2.
Liu F, Iqbal K, Grundke-Iqbal I, Hart G, Gong C . O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29):10804-9. PMC: 490015. DOI: 10.1073/pnas.0400348101. View

3.
Hou Y, Wei Y, Lautrup S, Yang B, Wang Y, Cordonnier S . NAD supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING. Proc Natl Acad Sci U S A. 2021; 118(37). PMC: 8449423. DOI: 10.1073/pnas.2011226118. View

4.
Xie N, Zhang L, Gao W, Huang C, Huber P, Zhou X . NAD metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020; 5(1):227. PMC: 7539288. DOI: 10.1038/s41392-020-00311-7. View

5.
Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau D, Zavala E . NAD supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018; 115(8):E1876-E1885. PMC: 5828618. DOI: 10.1073/pnas.1718819115. View